Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02596360
Other study ID # CHU-0248
Secondary ID 2015-003271-30
Status Completed
Phase Phase 1
First received October 19, 2015
Last updated March 31, 2016
Start date November 2015
Est. completion date March 2016

Study information

Verified date March 2016
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

The aim of this study is to assess the anti-hyperalgesic effect of dextromethorphan in healthy volunteers compared to placebo.


Description:

This is a cross-over group, double-blind, randomized clinical trial in healthy volunteers comparing dextromethorphan and inactive control on freeze-induced hyperalgesia, experimental pain, diffuse noxious inhibitory control (DNIC), pupillary reaction and reaction time.

The influence of CYP3A4 and MDR1 polymorphism on the dextromethorphan analgesic efficacy will be measured.

The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).

Each study sequence consists of 3 assessment days (Day -1, Day 0 = first treatment administration and Day 1).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy male volunteers

- Aged between 18 and 45 years

- CYP2D6 Extensive and Intermediate metabolizers

- Body mass index (BMI) between 19 and 30 kg/m2

- Systolic blood pressure between 100 and 150 mmHg, diastolic blood pressure between 50 and 90 mmHg, heart rate between 45 and 90 beats per minute

- Without treatment during the 7 days before inclusion specially no use of analgesic and anti-inflammatory drugs

- Cooperation and understanding enough to conform to the study obligations

- Having given free informed written consent

- Affiliated to the French Social Security

- Inscription or acceptation of inscription in the national register of volunteers involved in trials.

Exclusion Criteria:

- Hypersensitivity to the active substance or to any of the excipients

- Lactose intolerance

- Hypertension

- History of stroke

- Severe heart failure

- Severe hepatic impairment

- Shortness of breath

- Congenital galactosemia, glucose-galactose malabsorption, lactase deficiency

- Association with linezolid

- Pre-existence or history of peripheral neuropathy due to a cause different from neurotoxic chemotherapy

- Diabetes (type I and II)

- CYP2D6 Poor and Ultra-rapid metabolizers

- AST, ALT, total bilirubin twice the average

- Dextromethorphan intake during the 7 days before inclusion

- Medical and surgical history incompatible with the study

- Disease progression during inclusion

- Excessive consumption of alcohol (> 50g/day), tobacco (= 10 cigarettes/day), coffee, tea or drinks with caffeine (equivalent to more than 4 cups a day) or any addiction to drugs

- Subject lacking concentration during tests training and low test results reproducibility

- Subject does not meet the selection criteria for its ability to discriminate sensations to noxious stimuli during psychometric tests

- Subject exclusion period, or the total allowable compensation exceeded

- Subject undergoing a measure of legal protection (guardianship, supervision

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Pulmodexane® 30mg
The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
lactose
The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).

Locations

Country Name City State
France CHU Clermont-Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the curve (AUC) of percentage changes in mechanical pain thresholds (MPT) using electronic von frey in secondary hyperalgesic zone (Z2) at Day 0 after treatment administration: 1 hour post-dose (T0+1h), 2 hours post-dose (T0+2h) and 3 hours post-dose (T0+3h). No
Secondary Area under the curve (AUC) of percentage changes in mechanical pain thresholds (MPT) using electronic von frey in control skin zone (Z0) and primary hyperalgesic zone (Z1) at D0 T0+1h, T0+2h and T0+3h after treatment administration No
Secondary Percentage changes in mechanical pain thresholds (MPT) using electronic von frey in control skin zone (Z0) at Day 0 after treatment administration: 1 hour post-dose (T0+1h), 2 hours post-dose (T0+2h) and 3 hours post-dose (T0+3h). No
Secondary Percentage changes in mechanical pain thresholds (MPT) using electronic von frey in primary hyperalgesic zone (Z1) at Day 0 30 min before treatment (T0-30min ) and at Day 0 after treatment administration: 1 hour post-dose (T0+1h), 2 hours post-dose (T0+2h) and 3 hours post-dose (T0+3h) and at Day 1 after treatment administration: 24,5 hours post-dose (T0+24h30). No
Secondary Conditioned Pain Modulation (CPM) assessment at Day -1 before treatment and Day 0 30 min before treatment (T0-30min) No
Secondary Reaction time assessment using RTI CANTAB® test at Day -1 before treatment and Day 0 30 min before treatment (T0-30min), after treatment administration: 1 hour post-dose (T0+1h) and 3 hours post-dose (T0+3h) and at Day 1 after treatment administration: 24,5 hours post-dose (T0+24h30). No
Secondary Determination of potential central effects of dextromethorphan measuring pupillary reaction Determination of potential central effects of dextromethorphan measuring pupillary reaction assessing the diameter of the pupil in real time in scotopic conditions (e.g. size variation [mm]; contraction speed [mm.s-1]; contraction latency [ms]) at Day 0 30 min before treatment (T0-30min ) and at Day 0 after treatment administration: 1 hour post-dose (T0+1h), 2 hours post-dose (T0+2h) and 3 hours post-dose (T0+3h) and at Day 1 after treatment administration: 24,5 hours post-dose (T0+24h30).
- Study of genetic polymorphism of cytochrome P450 3A4 and MDR1 gene through study completion, up to 6 months.
at Day 0 30 min before treatment (T0-30min ) and at Day 0 after treatment administration: 1 hour post-dose (T0+1h), 2 hours post-dose (T0+2h) and 3 hours post-dose (T0+3h) and at Day 1 after treatment administration: 24,5 hours post-dose (T0+24h30). No
Secondary Study of genetic polymorphism of cytochrome P450 3A4 and genetic polymorphism of MDR1 gene up to 6 months. No
Secondary Dosage of plasma concentration of dextromethorphan and dextromethorphan's metabolites from blood collections at Day 0 30 min before treatment (T0-30min ) and at Day 0 after treatment administration: 2 hours post-dose (T0+2h) and at Day 1 after treatment administration: 24,5 hours post-dose (T0+24h30). No
See also
  Status Clinical Trial Phase
Completed NCT01301079 - Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Phase 3
Completed NCT00833755 - Effect of Ketamine on Opioid-Induced Hyperalgesia N/A
Completed NCT00279032 - GW406381 In Patients With Peripheral Nerve Injury Phase 1
Completed NCT03793790 - The Role of Learning in Nocebo Hyperalgesia N/A
Completed NCT03985995 - Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults N/A
Completed NCT04199858 - Electrophysiological Correlates of Nocebo Effects on Pain N/A
Not yet recruiting NCT02934763 - Opioid Induced Hyperalgesia (OIH) Modulation With Propranolol Phase 4
Completed NCT02938455 - DNA Methylation and Perioperative Pain Treatment
Completed NCT02253966 - Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty Phase 2
Completed NCT02653703 - L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain N/A
Completed NCT01702389 - Opioid-induced Hyperalgesia After Remifentanil Infusion Phase 4
Terminated NCT01615510 - Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models Phase 1
Completed NCT00218374 - Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia N/A
Completed NCT00387413 - A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers Phase 1
Completed NCT04197154 - Pain-related Fear as a Facilitator of Nocebo Hyperalgesia N/A
Completed NCT02976337 - Effect of High-dose Naloxone Following Third Molar Extraction Phase 2
Completed NCT03354624 - Cortical Neuroplasticity by Muscle Pain of Pain-induced Plasticity N/A
Recruiting NCT01480765 - Preventing Pain After Heart Surgery Phase 4
Recruiting NCT01015482 - The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun) Phase 4
Completed NCT01025245 - Effect of Intraoperative Magnesium on Remifentanil-induced Postoperative Hyperalgesia After Thyroidectomy Phase 4